Mineralocorticoid receptor antagonists (MRAs) are key agents in guideline‐oriented drug
therapy for cardiovascular diseases such as chronic heart failure with reduced ejection …

During the recent 30 years, there has been a dramatic increase in knowledge about the role
of aldosterone and the mineralocorticoid receptor (MR) in the pathophysiology of …

Background: The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease
Progression in Diabetic Kidney Disease) evaluated the effect of the nonsteroidal, selective …

Abstract Purpose of Review We aim to review the mechanism of action and safety profile of
mineralocorticoid receptor antagonists (MRAs) and discuss the differences between …

Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of
developing cardiovascular (CV) complications despite treatment with renin-angiotensin …

Activation of the mineralocorticoid receptor (MR) in the distal nephron by its ligand,
aldosterone, plays an important role in sodium reabsorption and blood pressure regulation …

Finerenone (Kerendia®), a first-in-class, orally administered, selective, nonsteroidal
mineralocorticoid receptor antagonist (MRA), is being developed by Bayer HealthCare …

Albuminuria is an early marker of renovascular damage associated to an increase in
oxidative stress. The Munich Wistar Frömter (MWF) rat is a model of chronic kidney disease …

Perception of the role of the aldosterone/mineralocorticoid receptor (MR) ensemble has
been extended from a previously renal epithelial-centered focus on sodium and volume …

Aldosterone controls salt–water homeostasis by acting on the mineralocorticoid receptor
(MR), a ligand-activated transcription factor, in kidney epithelial cells. However, it is now …